Daiwa Securities Group’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-464
| Closed | -$11K | – | 1363 |
|
|
2023
Q4 | $11K | Buy |
464
+123
| +36% | +$2.19K | ﹤0.01% | 1166 |
|
|
2023
Q3 | $5K | Hold |
341
| – | – | ﹤0.01% | 1167 |
|
|
2023
Q2 | $4K | Hold |
341
| – | – | ﹤0.01% | 1208 |
|
|
2023
Q1 | $3K | Hold |
341
| – | – | ﹤0.01% | 1198 |
|
|
2022
Q4 | $2K | Buy |
341
+189
| +124% | +$718 | ﹤0.01% | 1247 |
|
|
2022
Q3 | $1K | Hold |
152
| – | – | ﹤0.01% | 1326 |
|
|
2022
Q2 | $0 | Hold |
152
| – | – | ﹤0.01% | 1453 |
|
|
2022
Q1 | $0 | Hold |
152
| – | – | ﹤0.01% | 1433 |
|
|
2021
Q4 | $1K | Hold |
152
| – | – | ﹤0.01% | 1371 |
|
|
2021
Q3 | $1K | Hold |
152
| – | – | ﹤0.01% | 1294 |
|
|
2021
Q2 | $1K | Hold |
152
| – | – | ﹤0.01% | 1233 |
|
|
2021
Q1 | $1K | Hold |
152
| – | – | ﹤0.01% | 1244 |
|
|
2020
Q4 | $1K | Sell |
152
-226
| -60% | -$1.71K | ﹤0.01% | 1226 |
|
|
2020
Q3 | $3K | Hold |
378
| – | – | ﹤0.01% | 1126 |
|
|
2020
Q2 | $1K | Hold |
378
| – | – | ﹤0.01% | 1199 |
|
|
2020
Q1 | $1K | Hold |
378
| – | – | ﹤0.01% | 1202 |
|
|
2019
Q4 | $1K | Hold |
378
| – | – | ﹤0.01% | 1193 |
|
|
2019
Q3 | $2K | Hold |
378
| – | – | ﹤0.01% | 1139 |
|
|
2019
Q2 | $3K | Hold |
378
| – | – | ﹤0.01% | 1136 |
|
|
2019
Q1 | $5K | Sell |
378
-322
| -46% | -$3.42K | ﹤0.01% | 1084 |
|
|
2018
Q4 | $6K | Buy |
+700
| New | +$6.66K | ﹤0.01% | 1047 |
|
Other funds holding CBAY
Daiwa Securities Group's CBAY Position: Q1 2024 in Review
Daiwa Securities Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 464 shares — an estimated $11K sold.
Daiwa Securities Group first reported a position in CBAY in Q4 2018 and held it in 21 quarters. The position peaked at $11K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Daiwa Securities Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Daiwa Securities Group sold 464 Cymabay Therapeutics shares in Q1 2024, an estimated $11K.
- Daiwa Securities Group first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 21 quarters.
- Daiwa Securities Group's Cymabay Therapeutics position peaked at $11K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Daiwa Securities Group's 13F filing for Q1 2024, filed 2 May 2024.